AUSTEDO has a differentiated pharmacokinetic (PK) profile
vs tetrabenazine1

AUSTEDO features deuterium, which extends the half-life of active therapeutic metabolites (~9-10 hours)1-3:

  • Helps maintain more consistent drug levels, independent of individual patient metabolism

Plasma Concentrations of Alpha and Beta Metabolites over 24 Hours—PK Model1

Plasma   Concentrations of Alpha and   Beta Metabolites Over 24   hours-Pharmacokinetic (PK) Model. 3 Peaks = Tetrabenazine 3 times a day   vs 2 Peaks = AUSTEDO®   (deutetrabenazine) tablets   twice daily. The correlation   between plasma levels and   clinical efficacy has not been   established. Plasma   Concentrations of Alpha and   Beta Metabolites Over 24   hours-Pharmacokinetic (PK) Model. 3 Peaks = Tetrabenazine 3 times a day   vs 2 Peaks = AUSTEDO®   (deutetrabenazine) tablets   twice daily. The correlation   between plasma levels and   clinical efficacy has not been   established.

Slower rate of metabolism allows for twice-
daily dosing of AUSTEDO

PK simulations of area under the curve (AUC) matched exposure to active metabolites based on dosing regimens of AUSTEDO (9 mg twice daily) and tetrabenazine (12.5 mg 3 times a day) at steady state.1

  • Twice-daily dosing of AUSTEDO showed a slower rate of rise, lower peak-to-trough fluctuations, and reduced Cmax vs tetrabenazine

Deuteration of AUSTEDO allows for more consistent drug levels. VMAT2 inhibition with AUSTEDO can help regulate dopamine function, which is a key factor for control of movement1‑3

VMAT2, vesicular monoamine transporter 2.

REFERENCES: 1. Data on file. North Wales, PA: Teva Neuroscience, Inc. 2. Tung R. The development of deuterium-containing drugs. Innov Pharm Technol. 2010;32(32):24-28. 3. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc.